论文部分内容阅读
新近日本武田药厂研制的AO-128是一种α-糖苷酶阻断剂,可阻断双糖水解,从而延迟或抑制肠道对单精的吸收,使血糖水平降低。田港朝产等为进一步观察AO-128对NIDDM患者餐后高血糖的影响,进行了研究。对NIDDM病人28例,年龄20～70岁,在不用胰岛素、不饮酒、非妊娠者,心肝肾胰无重笃合并症,无慢性胃肠病的前题下,观察4周再治疗8周,口服AO-128片,0.6mg或0.9mg/d,分3次,于治疗8周后测餐后1h、2h血糖水平,血糖曲线下面积,血中胰岛素1h值,HbAlc及果糖胺,均明显降低,空腹时血
Recently, Takeda Pharmaceutical Co., Ltd. developed AO-128 is an α-glucosidase blocking agent, which can block the hydrolysis of disaccharides to delay or inhibit intestinal absorption of monosodium, so that blood glucose levels decreased. In order to further observe the effect of AO-128 on postprandial hyperglycemia in patients with NIDDM, a study was conducted. 28 cases of NIDDM patients, aged 20 to 70 years old, without insulin, non-alcoholic, non-pregnant, heart and kidney nephropathy no serious complications, no chronic gastrointestinal disease in the former, observed for 4 weeks and then treated for 8 weeks , AO-128 orally, 0.6mg or 0.9mg / d in 3 times. After 8 weeks of treatment, the blood glucose level, the area under the blood glucose curve, the blood insulin 1h, HbAlc and fructosamine Significantly lower fasting blood